Recombinant Human SUSD2 protein (rFc Tag)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

C-rFc

Activity

not tested

Cat no : Eg2627

---

Validation Data Gallery

• 

  Purity of Recombinant Human SUSD2 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) condition and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Human SUSD2 protein Gln28-Arg782 (Accession# Q9UGT4) with a rabbit IgG Fc tag at the C-terminus.
• GeneID: 56241
• Accession: Q9UGT4
• PredictedSize: 109.4 kDa
• SDS-PAGE: 50-55 kDa and 70-85 kDa, reducing (R) condition
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

Sushi domain containing 2 (SUSD2) is a type I transmembrane protein that encodes a type I transmembrane protein containing several functional domains inherent to adhesion molecules, which are frequently found in molecules associated with cell-cell and cell-matrix adhesion. Expression of SUSD2 in cancer cells correlates either positively or negatively with tumor growth, depending on the cancer type. Expression of Susd2 by mammary tumors promotes many aspects of breast tumorigenesis, including tumor immune evasion, angiogenesis and metastasis.

References:

1. Sheets, J. N., et al. (2020).  Oncotarget. Jun 16;11(24):2290-2301.
2. Zhao B, et al. (2022). Nat Immunol. Nov;23(11):1588-1599.
3. Patrick, M. E., et al. (2019). Int J Mol Sci. Aug 5;20(15):3814. 
4. Watson, A. P., et al. (2013). Mol Cancer Res. Jan;11(1):74-85.